Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reached a significant milestone in its GARDian clinical trial for OCU410ST, a promising gene therapy aimed at treating Stargardt disease. The company …
Ocugen Advances Gene Therapy Trial for Stargardt Disease Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received approval from Health Canada to begin the Phase 3 liMeliGhT clinical trial for their OCU400 gene therapy. This trial aims to …
Ocugen Expands Gene Therapy Trial to Canada Read More
CONSHOHOCKEN, PA — Alcura, a part of Cencora, has received a Manufacturing and Importation Authorization (MIA) license for cell and gene therapies (CGT) from the Spanish Agency of Medicines and …
Alcura Secures MIA License to Enhance Cell and Gene Therapy Importation Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received approval from the Food and Drug Administration to begin its expanded access program (EAP) for the treatment of adult patients with …
Ocugen Receives FDA Approval for Expanded Access Program for Retinitis Pigmentosa Treatment Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the completion of dosing in the third cohort of its Phase 1/2 ArMaDa clinical trial for OCU410, a novel gene …
Ocugen Completes Dosing in Phase 1/2 Trial for Gene Therapy to Treat Geographic Atrophy Read More
WAYNE, PA, and TULLINGE, Sweden — XyloCor Therapeutics, Inc. recently secured licensing rights to the Extroducer® Infusion Catheter System from SmartWise. This innovative device is set to revolutionize the delivery …
XyloCor Therapeutics and SmartWise Team Up to Enhance Gene Therapy Delivery Read More
WASHINGTON, D.C. — This week, in a significant step for the medical world and hope for patients, the U.S. Food and Drug Administration expanded the approval of Elevidys, a gene …
FDA Broadens Approval of Elevidys Gene Therapy for Duchenne Muscular Dystrophy Patients Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400, a gene therapy candidate for retinitis pigmentosa …
Ocugen Doses First Patient in Phase 3 Trial for Retinitis Pigmentosa Therapy Read More
GLENOLDEN, PA — The Charcot-Marie-Tooth Association (CMTA) has announced a $240,000 investment in gene replacement therapy targeting CMT4A, a severe form of the disease. This initiative, led by Dr. Xin …
CMTA Invests $240K in Gene Therapy for Rare Nerve Disorder Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a positive outcome from the Data and Safety Monitoring Board (DSMB) review of its Phase 1/2 ArMaDa clinical trial for OCU410, a …
Ocugen’s Gene Therapy Shows Promise in Early Trial for Age-Related Macular Degeneration Read More